{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:31:02Z","timestamp":1789381862389,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001656","name":"Helmholtz-Gemeinschaft","doi-asserted-by":"publisher","award":["SO-96"],"award-info":[{"award-number":["SO-96"]}],"id":[{"id":"10.13039\/501100001656","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001656","name":"Helmholtz-Gemeinschaft","doi-asserted-by":"publisher","award":["SO-96"],"award-info":[{"award-number":["SO-96"]}],"id":[{"id":"10.13039\/501100001656","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001656","name":"Helmholtz-Gemeinschaft","doi-asserted-by":"publisher","award":["SO-96"],"award-info":[{"award-number":["SO-96"]}],"id":[{"id":"10.13039\/501100001656","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001656","name":"Helmholtz-Gemeinschaft","doi-asserted-by":"publisher","award":["KA1-Co-02"],"award-info":[{"award-number":["KA1-Co-02"]}],"id":[{"id":"10.13039\/501100001656","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KI2006D, 01KI20328A, 01KX2021"],"award-info":[{"award-number":["01KI2006D, 01KI20328A, 01KX2021"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010570","name":"Nieders\u00e4chsisches Ministerium f\u00fcr Wissenschaft und Kultur","doi-asserted-by":"publisher","award":["14-76103-184, MWK HZI COVID-19"],"award-info":[{"award-number":["14-76103-184, MWK HZI COVID-19"]}],"id":[{"id":"10.13039\/501100010570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["PO 716\/11-1, PO 716\/14-1"],"award-info":[{"award-number":["PO 716\/11-1, PO 716\/14-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["39087428"],"award-info":[{"award-number":["39087428"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Helmholtz-Zentrum f\u00fcr Infektionsforschung GmbH (HZI)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>SARS-CoV-2 variants accumulating immune escape mutations provide a significant risk to vaccine-induced protection against infection. The novel variant of concern (VoC) Omicron BA.1 and its sub-lineages have the largest number of amino acid alterations in its Spike protein to date. Thus, they may efficiently escape recognition by neutralizing antibodies, allowing breakthrough infections in convalescent and vaccinated individuals in particular in those who have\u00a0only received\u00a0a primary immunization scheme. We analyzed neutralization activity of sera from individuals after vaccination with all mRNA-, vector- or heterologous immunization schemes currently available in Europe by in vitro neutralization assay at peak response towards SARS-CoV-2 B.1, Omicron sub-lineages BA.1, BA.2, BA.2.12.1, BA.3, BA.4\/5, Beta and Delta pseudotypes and also provide longitudinal follow-up data from BNT162b2 vaccinees. All vaccines apart from Ad26.CoV2.S showed high levels of responder rates (96\u2013100%) towards the\u00a0SARS-CoV-2 B.1 isolate, and minor to moderate reductions in neutralizing Beta and Delta VoC pseudotypes. The novel Omicron variant and its sub-lineages had the biggest impact, both in terms of response rates and neutralization titers. Only mRNA-1273 showed a 100% response rate to Omicron BA.1 and induced the highest level of neutralizing antibody titers, followed by heterologous prime-boost approaches. Homologous BNT162b2 vaccination, vector-based AZD1222\u00a0and Ad26.CoV2.S performed less well with peak responder rates of 48%, 56% and 9%, respectively. However, Omicron responder rates in BNT162b2 recipients were maintained in our six month longitudinal follow-up indicating that individuals with cross-protection against Omicron maintain it over time. Overall, our data strongly argue for booster doses in individuals who were previously vaccinated with BNT162b2, or a vector-based primary immunization scheme.<\/jats:p>","DOI":"10.1038\/s41598-022-22552-y","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T10:04:10Z","timestamp":1668765850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations"],"prefix":"10.1038","volume":"12","author":[{"given":"Henning","family":"Jacobsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Strengert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrike","family":"Maa\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Alberto","family":"Ynga Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Katzmarzyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Harries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulfert","family":"Rand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Abassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonsu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"L\u00fcddecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Metzdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Ortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana-Kristin","family":"Heise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Castell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gornyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Gl\u00f6ckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Melhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Kemmling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Dulovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Marsall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"H\u00e4ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Junker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Schneiderhan-Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"P\u00f6hlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Cicin-Sain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"22552_CR1","unstructured":"WHO. WHO Coronavirus (COVID-19) Dashboard 2021 [Available from: https:\/\/covid19.who.int\/."},{"issue":"6534","key":"22552_CR2","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1126\/science.abg7404","volume":"371","author":"DM Altmann","year":"2021","unstructured":"Altmann, D. M., Boyton, R. J. & Beale, R. Immunity to SARS-CoV-2 variants of concern. Science 371(6534), 1103\u20131104 (2021).","journal-title":"Science"},{"issue":"7","key":"22552_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal, J. et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N. Engl. J. Med. 385(7), 585\u2013594 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"22552_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","volume":"22","author":"K Tao","year":"2021","unstructured":"Tao, K. et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. 22(12), 757\u2013773 (2021).","journal-title":"Nat. Rev. Genet."},{"issue":"11","key":"22552_CR5","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27(11), 2032\u20132040 (2021).","journal-title":"Nat. Med."},{"issue":"7","key":"22552_CR6","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s41591-021-01432-4","volume":"27","author":"F Krammer","year":"2021","unstructured":"Krammer, F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat Med. 27(7), 1147\u20131148 (2021).","journal-title":"Nat Med."},{"key":"22552_CR7","unstructured":"Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic Review. Available: https:\/\/view-hub.org\/sites\/default\/files\/2022-04\/COVID19%20Vaccine%20Effectiveness%20Transmission%20Studies%20-%20Summary%20Tables_20220407.pdf. Updated April 7, 2022."},{"key":"22552_CR8","unstructured":"WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern 2021 [Available from: https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern."},{"issue":"1","key":"22552_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/22221751.2021.2017757","volume":"11","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. The significant immune escape of pseudotyped SARS-CoV-2 variant omicron. Emerg. Microbes Infect. 11(1), 1\u20135 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"22552_CR10","doi-asserted-by":"crossref","unstructured":"Cele S, Jackson L, Khan K, Khoury DS, Moyo-Gwete T, Tegally H, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv (2021).","DOI":"10.1101\/2021.12.08.21267417"},{"key":"22552_CR11","doi-asserted-by":"crossref","unstructured":"Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies. medRxiv. (2021).","DOI":"10.1101\/2021.12.07.21267432"},{"issue":"7","key":"22552_CR12","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1056\/NEJMc2119236","volume":"386","author":"A R\u00f6ssler","year":"2022","unstructured":"R\u00f6ssler, A., Riepler, L., Bante, D., von Laer, D. & Kimpel, J. SARS-CoV-2 omicron variant neutralization in serum from vaccinated and convalescent persons. N. Engl. J. Med. 386(7), 698\u2013700 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"22552_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12916-022-02312-5","volume":"20","author":"M Schubert","year":"2022","unstructured":"Schubert, M. et al. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 omicron variant. BMC Med. 20(1), 102 (2022).","journal-title":"BMC Med."},{"issue":"3","key":"22552_CR14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","volume":"185","author":"M Hoffmann","year":"2022","unstructured":"Hoffmann, M. et al. The omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell 185(3), 447\u201356.e11 (2022).","journal-title":"Cell"},{"issue":"10321","key":"22552_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0140-6736(21)02844-0","volume":"399","author":"W Dejnirattisai","year":"2022","unstructured":"Dejnirattisai, W. et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet (London, England). 399(10321), 234\u2013236 (2022).","journal-title":"Lancet (London, England)."},{"issue":"3","key":"22552_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","volume":"185","author":"WF Garcia-Beltran","year":"2022","unstructured":"Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 omicron variant. Cell 185(3), 457\u201366.e4 (2022).","journal-title":"Cell"},{"issue":"6","key":"22552_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMc2119641","volume":"386","author":"F Schmidt","year":"2022","unstructured":"Schmidt, F. et al. Plasma neutralization of the SARS-CoV-2 omicron variant. N. Engl. J. Med. 386(6), 599\u2013601 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"48","key":"22552_CR18","first-page":"824","volume":"118","author":"D Gornyk","year":"2021","unstructured":"Gornyk, D. et al. SARS-CoV-2 seroprevalence in Germany. Dtsch. Arztebl. Int. 118(48), 824 (2021).","journal-title":"Dtsch. Arztebl. Int."},{"issue":"1","key":"22552_CR19","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/s41467-021-20973-3","volume":"12","author":"M Becker","year":"2021","unstructured":"Becker, M. et al. Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. Nat. Commun. 12(1), 1152 (2021).","journal-title":"Nat. Commun."},{"issue":"3","key":"22552_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109017","volume":"35","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann, M. et al. SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Rep. 35(3), 109017 (2021).","journal-title":"Cell Rep."},{"issue":"9","key":"22552_CR21","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","volume":"184","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184(9), 2384\u20132393 (2021).","journal-title":"Cell"},{"issue":"12","key":"22552_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189073","volume":"12","author":"C Brinkmann","year":"2017","unstructured":"Brinkmann, C. et al. The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells. PLoS ONE 12(12), e0189073 (2017).","journal-title":"PLoS ONE"},{"issue":"3","key":"22552_CR23","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","volume":"85","author":"M Hoffmann","year":"2022","unstructured":"Hoffmann, M. et al. The omicron variant is highly resistant against antibody-mediated neutralization\u2014implications for control of the COVID-19 pandemic. Cell 85(3), 447\u2013456 (2022).","journal-title":"Cell"},{"issue":"2","key":"22552_CR24","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1128\/JVI.01381-18","volume":"93","author":"H Kleine-Weber","year":"2019","unstructured":"Kleine-Weber, H. et al. Mutations in the spike protein of middle east respiratory syndrome coronavirus transmitted in korea increase resistance to antibody-mediated neutralization. J. Virol. 93(2), 1381\u20131418 (2019).","journal-title":"J. Virol."},{"issue":"10","key":"22552_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025858","volume":"6","author":"M Berger Rentsch","year":"2011","unstructured":"Berger Rentsch, M. & Zimmer, G. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. PLoS ONE 6(10), e25858 (2011).","journal-title":"PLoS ONE"},{"key":"22552_CR26","doi-asserted-by":"crossref","unstructured":"Dulovic A, Kessel B, Harries M, Becker M, Ortmann J, Griesbaum J, et al. Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany. Frontiers in Immunology 13 (2022).","DOI":"10.3389\/fimmu.2022.828053"},{"key":"22552_CR27","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.14.21267772","author":"A Aggarwal","year":"2021","unstructured":"Aggarwal, A. et al. SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. MedRxiv https:\/\/doi.org\/10.1101\/2021.12.14.21267772 (2021).","journal-title":"MedRxiv"},{"key":"22552_CR28","unstructured":"Impfquotenmonitoring-2021\u201312\u201322T07_55_40. https:\/\/github.com\/evilpie\/Impfquotenmonitoring."},{"key":"22552_CR29","unstructured":"RKI. Digitales Impfquotenmonitoring zur COVID-19-Impfung: https:\/\/www.rki.de\/DE\/Content\/InfAZ\/N\/Neuartiges_Coronavirus\/Daten\/Impfquoten-Tab.html. accessed on 12th September 2022."},{"issue":"69","key":"22552_CR30","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1126\/sciimmunol.abo2202","volume":"7","author":"CH GeurtsvanKessel","year":"2022","unstructured":"GeurtsvanKessel, C. H. et al. Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. Sci Immunol. 7(69), 2202 (2022).","journal-title":"Sci Immunol."},{"key":"22552_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100208","volume":"10","author":"P Naaber","year":"2021","unstructured":"Naaber, P. et al. Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study. Lancet Reg. Health Europe 10, 100208 (2021).","journal-title":"Lancet Reg. Health Europe"},{"issue":"15","key":"22552_CR32","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1001\/jama.2021.15125","volume":"326","author":"D Steensels","year":"2021","unstructured":"Steensels, D., Pierlet, N., Penders, J., Mesotten, D. & Heylen, L. Comparison of SARS-CoV-2 antibody response following vaccination With BNT162b2 and mRNA-1273. JAMA 326(15), 1533\u20131535 (2021).","journal-title":"JAMA"},{"key":"22552_CR33","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.12.21257102","author":"M Shrotri","year":"2021","unstructured":"Shrotri, M. et al. Spike-antibody responses to ChAdOx1 and BNT162b2 vaccines by demographic and clinical factors (Virus Watch study). MedRxiv https:\/\/doi.org\/10.1101\/2021.05.12.21257102 (2021).","journal-title":"MedRxiv"},{"key":"22552_CR34","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.15.21267805","author":"NA Doria-Rose","year":"2021","unstructured":"Doria-Rose, N. A. et al. Booster of mRNA-1273 vaccine reduces SARS-CoV-2 omicron escape from neutralizing antibodies. MedRxiv https:\/\/doi.org\/10.1101\/2021.12.15.21267805 (2021).","journal-title":"MedRxiv"},{"issue":"8","key":"22552_CR35","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41591-021-01410-w","volume":"27","author":"E Pritchard","year":"2021","unstructured":"Pritchard, E. et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat. Med. 27(8), 1370\u20131378 (2021).","journal-title":"Nat. Med."},{"issue":"9","key":"22552_CR36","doi-asserted-by":"publisher","first-page":"2126882","DOI":"10.1001\/jamanetworkopen.2021.26882","volume":"4","author":"AJ Siegler","year":"2021","unstructured":"Siegler, A. J. et al. Trajectory of COVID-19 vaccine hesitancy over time and association of initial vaccine hesitancy with subsequent vaccination. JAMA Netw. Open 4(9), 2126882 (2021).","journal-title":"JAMA Netw. Open"},{"key":"22552_CR37","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.30.21267519","author":"D Junker","year":"2022","unstructured":"Junker, D. et al. Antibody binding and ACE2 binding inhibition is significantly reduced for the omicron variant compared to all other variants of concern. MedRxiv https:\/\/doi.org\/10.1101\/2021.12.30.21267519 (2022).","journal-title":"MedRxiv"},{"issue":"6581","key":"22552_CR38","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1126\/science.abn7591","volume":"375","author":"A Muik","year":"2022","unstructured":"Muik, A. et al. Neutralization of SARS-CoV-2 omicron by BNT162b2 mRNA vaccine\u2013elicited human sera. Science 375(6581), 678\u2013680 (2022).","journal-title":"Science"},{"issue":"16","key":"22552_CR39","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMc2201849","volume":"386","author":"J Yu","year":"2022","unstructured":"Yu, J. et al. Neutralization of the SARS-CoV-2 omicron BA.1 and BA.2 variants. N. Engl. J. Med. 386(16), 1579\u20131580 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"22552_CR40","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/cid\/ciab1041","volume":"75","author":"L Lu","year":"2021","unstructured":"Lu, L. et al. Neutralization of severe acute respiratory syndrome coronavirus 2 omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients. Clin. Infect. Dis. 75(1), 822\u2013826 (2021).","journal-title":"Clin. Infect. Dis."},{"issue":"18","key":"22552_CR41","doi-asserted-by":"publisher","first-page":"2200178","DOI":"10.2807\/1560-7917.ES.2022.27.18.2200178","volume":"27","author":"SM Cheng","year":"2022","unstructured":"Cheng, S. M. et al. SARS-CoV-2 omicron variant BA.2 neutralisation in sera of people with comirnaty or coronavac vaccination, infection or breakthrough infection Hong Kong 2020 to 2022. Eurosurveillance 27(18), 2200178 (2022).","journal-title":"Eurosurveillance"},{"issue":"3","key":"22552_CR42","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41591-022-01704-7","volume":"28","author":"SMS Cheng","year":"2022","unstructured":"Cheng, S. M. S. et al. Neutralizing antibodies against the SARS-CoV-2 omicron variant BA.1 following homologous and heterologous coronavac or BNT162b2 vaccination. Nat. Med. 28(3), 486\u2013489 (2022).","journal-title":"Nat. Med."},{"issue":"3","key":"22552_CR43","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41591-022-01705-6","volume":"28","author":"E P\u00e9rez-Then","year":"2022","unstructured":"P\u00e9rez-Then, E. et al. Neutralizing antibodies against the SARS-CoV-2 delta and omicron variants following heterologous coronavac plus BNT162b2 booster vaccination. Nat. Med. 28(3), 481\u2013485 (2022).","journal-title":"Nat. Med."},{"issue":"11","key":"22552_CR44","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.cell.2022.04.009","volume":"185","author":"RR Goel","year":"2022","unstructured":"Goel, R. R. et al. Efficient recall of omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell 185(11), 1875\u201387.e8 (2022).","journal-title":"Cell"},{"issue":"14","key":"22552_CR45","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1056\/NEJMc2202542","volume":"386","author":"G Regev-Yochay","year":"2022","unstructured":"Regev-Yochay, G. et al. Efficacy of a fourth dose of covid-19 mRNA vaccine against omicron. N. Engl. J. Med. 386(14), 1377\u20131380 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"22552_CR46","first-page":"994","volume":"11","author":"AMK Tolah","year":"2021","unstructured":"Tolah, A. M. K. et al. Evaluation of a pseudovirus neutralization assay for SARS-CoV-2 and correlation with live virus-based micro neutralization assay. Diagnostics (Basel, Switzerland). 11(6), 994 (2021).","journal-title":"Diagnostics (Basel, Switzerland)."},{"issue":"9","key":"22552_CR47","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3390\/v12091011","volume":"12","author":"I Hyseni","year":"2020","unstructured":"Hyseni, I. et al. Characterisation of SARS-CoV-2 Lentiviral pseudotypes and correlation between pseudotype-based neutralisation assays and live virus-based micro neutralisation assays. Viruses 12(9), 1011 (2020).","journal-title":"Viruses"},{"key":"22552_CR48","unstructured":"Center JHCR. https:\/\/coronavirus.jhu.edu\/vaccines\/international accessed 12th September 2022."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22552-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22552-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22552-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T10:15:24Z","timestamp":1668766524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22552-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["22552"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-22552-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.21.21267898","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"assertion":[{"value":"23 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NSM was a speaker at Luminex user meetings in the past. The Natural and Medical Sciences Institute at the University of T\u00fcbingen is involved in applied research projects as a fee for services with the Luminex Corporation. The other authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19858"}}